Windtree Therapeutics to Be Delisted from Nasdaq

Written by Emily J. Thompson, Senior Investment Analyst

BNB-6.909%

FORM-2.024%

Source: Coinmarketcap

Updated: Aug 21 2025

0mins

Source: Coinmarketcap

Delisting from Nasdaq: Windtree Therapeutics is set to be delisted from the Nasdaq Capital Market due to failing to meet the minimum $1 bid price requirement for 30 consecutive business days, with trading suspension effective August 21, 2025.
Financial Performance: The company raised $60 million but reported a net loss of $10.64 million, highlighting ongoing financial struggles despite recent funding efforts.
Impact on Share Price: Following the delisting notice, Windtree's shares dropped by 77.21%, reflecting a significant decline in investor confidence and market liquidity.
Ongoing Compliance: Despite the delisting, Windtree continues to comply with SEC reporting requirements and asserts that its operations will not be affected by the transition to over-the-counter trading.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.